Guardant Health, Inc.

GH 10-Q · Q1 2026
API behind this page

GH Q1 2026 request

Playground key active
Request URL /api/financials?ticker=GH&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 301,665 203,471 +48.3%
Show Business Segments breakouts
Reportable Segment 301,665 203,471 +48.3%
Show Geography breakouts
Non Us 17,036 9,862 +72.7%
US 284,629 193,609 +47.0%
Cost of Revenue 104,919 74,723 +40.4%
Show Business Segments breakouts
Reportable Segment 101,560 72,185 +40.7%
Research & Development 91,038 88,521 +2.8%
Sales & Marketing 169,132 104,316 +62.1%
General & Administrative 57,926 46,952 +23.4%
Total Costs & Expenses 423,015 314,512 +34.5%
Operating Income -121,350 -111,041 -9.3%
Interest Income 11,151 9,112 +22.4%
Interest Expense -1,347 -791 -70.3%
Other Non-Operating Income (Expense) -157 7,851 -102.0%
Income Before Taxes -111,703 -94,869 -17.7%
Income Tax Expense (Benefit) 372 290 +28.3%
Net Income -112,075 -95,159 -17.8%
Show Business Segments breakouts
Reportable Segment -112,075 -95,159 -17.8%
Show Equity Components breakouts
Retained Earnings -112,075 -95,159 -17.8%
EPS (Basic) -0.85 -0.77 -10.4%
EPS (Diluted) -0.85 -0.77 -10.4%
Wtd Avg Shares (Basic) 131,273 123,871 +6.0%
Wtd Avg Shares (Diluted) 131,273 123,871 +6.0%
Revenue 301,665 203,471 +48.3%
Show Product Lines breakouts
Biopharma and data 52,977 45,376 +16.8%
Licensing and other 2,144 1,859 +15.3%
Oncology 204,954 150,559 +36.1%
Screening 41,590 5,677 +632.6%
Comprehensive Income -112,375 -94,616 -18.8%
Net Income Loss Available To Common Stockholders Basic -112,075 -95,159 -17.8%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 989,291 698,572 +41.6%
Available For Sale Securities Debt Securities Current 113,469 — —
Accounts Receivable 137,404 115,426 +19.0%
Inventory 83,851 77,256 +8.5%
Prepaid Expenses & Other Current Assets 43,490 35,772 +21.6%
Total Current Assets 1,367,505 927,026 +47.5%
Non-Current Assets
Restricted Cash Noncurrent 112,150 105,281 +6.5%
Show Litigation Case breakouts
TwinStrand Biosciences And University Of Washington vs. Guardant Health, Inc. 108.5 104.6 +3.7%
Property, Plant & Equipment 150,035 129,294 +16.0%
Operating Lease Right-of-Use Assets 153,906 140,500 +9.5%
Goodwill 77,257 — —
Other Non-Current Assets 28,895 32,555 -11.2%
Total Assets 1,915,291 1,344,226 +42.5%
Intangible Assets 4,712 6,280 -25.0%
Show Finite Lived Intangible Assets By Major Class breakouts
Licensing Agreements 4,712 5,818 -19.0%
Other Assets
Intangible Assets Net Excluding Goodwill 25,543 6,280 +306.7%
Current Liabilities
Accounts Payable 75,034 49,770 +50.8%
Accrued Employee Benefits Current 91,326 63,678 +43.4%
Accrued Liabilities 78,013 76,003 +2.6%
Deferred Revenue (Current) 47,772 36,302 +31.6%
Total Current Liabilities 292,145 225,753 +29.4%
Non-Current Liabilities
Convertible Debt Noncurrent 1,503,471 1,116,339 +34.7%
Operating Lease Liabilities 173,055 160,378 +7.9%
Other Non-Current Liabilities 127,693 92,545 +38.0%
Total Liabilities 2,096,364 1,595,015 +31.4%
Long-Term Debt 1,503,471 1,116,339 +34.7%
Show Debt Instrument breakouts
Convertible Senior Notes Due 2027 · Convertible Debt 488,860 487,756 +0.2%
Convertible Senior Notes Due 2031 · Convertible Debt 623,866 628,583 -0.8%
Convertible Senior Notes Due 2033 · Convertible Debt 390,745 — —
Contract With Customer Liability Noncurrent 8.9 7.7 +15.6%
Stockholders' Equity
Common Stock Value Outstanding 1 1 0.0%
Additional Paid-In Capital 2,930,665 2,472,272 +18.5%
Accumulated Other Comprehensive Income -5,152 -4,658 -10.6%
Retained Earnings -3,106,587 -2,673,394 -16.2%
Total Stockholders' Equity -181,073 -250,789 +27.8%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -5,152 -4,658 -10.6%
Additional Paid In Capital 2,930,665 2,472,272 +18.5%
Common Stock 1 1 0.0%
Retained Earnings -3,106,587 -2,673,394 -16.2%
Total Liabilities & Equity 1,915,291 1,344,226 +42.5%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Depreciation & Amortization 9,442 10,236 -7.8%
Non Cash Operating Lease Costs 8,561 7,870 +8.8%
Stock-Based Compensation 47,608 37,757 +26.1%
Accretion Amortization Of Discounts And Premiums Investments -6,986 -792 -782.1%
Proceeds From Interest Received 11,825 7,677 +54.0%
Other Non-Cash Items -727 1,732 -142.0%
Change in Accounts Receivable 942 -6,115 +115.4%
Change in Inventory 2,025 -6,173 +132.8%
Change in Prepaid & Other Assets -7,238 -3,072 -135.6%
Increase Decrease In Other Operating Assets 1,063 697 +52.5%
Increase Decrease In Accounts Payable Accrued And Other Liabilities -8,229 -1,537 -435.4%
Increase Decrease In Operating Lease Liabilities -8,604 -9,565 +10.0%
Change in Deferred Revenue -3,230 2,427 -233.1%
Net Cash from Operations -65,623 -62,689 -4.7%
Investing Activities
Purchases of Investments -249,936 — —
Proceeds From Sale And Maturity Of Marketable Securities 954,934 307,323 +210.7%
Capital Expenditures -5,580 -4,459 -25.1%
Net Cash from Investing 699,418 302,864 +130.9%
Financing Activities
Proceeds From Stock Options Exercised 3,651 768 +375.4%
Tax Withholding for Share Compensation -20,650 -15,497 -33.3%
Debt Issuance Costs -102 -12,138 +99.2%
Proceeds From Payments For Other Financing Activities -4,476 -3 -149100.0%
Net Cash from Financing -21,577 -66,850 +67.7%
Amortization of Financing Costs 1,178 702 +67.8%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -194 773 -125.1%
Net Change in Cash 612,024 174,098 +251.5%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1,101,441 803,853 +37.0%

Values in thousands USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key